The present study reports on the biocompatibility in vivo after intramuscular and subcutaneous administration in Balb/C mice of vinyl sulfone bearing p(HPMAm-lac1-2)-PEG- p(HPMAm-lac1-2)/thiolated hyaluronic acid hydrogels, designed as novel injectable biomaterials for potential application in the fields of tissue engineering and regenerative medicine.[3] Ultrasonography, used as a method to study hydrogel gelation and residence time in vivo, showed that, upon injection, the biomaterial efficiently formed a hydrogel by simultaneous thermal gelation and Michael addition cross-linking forming a viscoelastic spherical depot at the injection site. The residence time in vivo (20 days) was found shorter than that observed in vitro (32 days), indicating that the injected hydrogel was resorbed not only by chemical hydrolysis but also by cellular metabolism and/or enzymatic activity. Systemic biocompatibility was tested by analysing routine hematologic parameters at different time points (7, 14 and 21 days post administration) and histology of the main organs including the hematopoietic system. No statistically significant difference between parameters of the saline treated group and those of the hydrogel treated group was found. Importantly, a time-dependent decrease of important pro-inflammatory cytokines (TREM1, TNF-α, IL-1β) in cultured BMCs extracted from hydrogel treated mice was observed, possibly correlated to the anti-inflammatory effect of hyaluronic acid released in time as hydrogel degraded. This in vivo study established the suitability of the proposed hydrogel technology as promising matrix for tissue engineering and drug delivery. The possibility to apply the developed hydrogel technology in vivo will potentially bring advances in the biomedical and pharmaceutical fields.
In vivo biocompatibility of p(HPMAm-lac)-PEG hydrogels hybridized with hyaluronan
Censi, Roberta;Sabbieti, Maria Giovanna;Dubbini, Alessandra;Laus, Fulvio;Paggi, Emanuele;Marchegiani, Andrea;Agas, Dimitrios;Di Martino, Piera
2016-01-01
Abstract
The present study reports on the biocompatibility in vivo after intramuscular and subcutaneous administration in Balb/C mice of vinyl sulfone bearing p(HPMAm-lac1-2)-PEG- p(HPMAm-lac1-2)/thiolated hyaluronic acid hydrogels, designed as novel injectable biomaterials for potential application in the fields of tissue engineering and regenerative medicine.[3] Ultrasonography, used as a method to study hydrogel gelation and residence time in vivo, showed that, upon injection, the biomaterial efficiently formed a hydrogel by simultaneous thermal gelation and Michael addition cross-linking forming a viscoelastic spherical depot at the injection site. The residence time in vivo (20 days) was found shorter than that observed in vitro (32 days), indicating that the injected hydrogel was resorbed not only by chemical hydrolysis but also by cellular metabolism and/or enzymatic activity. Systemic biocompatibility was tested by analysing routine hematologic parameters at different time points (7, 14 and 21 days post administration) and histology of the main organs including the hematopoietic system. No statistically significant difference between parameters of the saline treated group and those of the hydrogel treated group was found. Importantly, a time-dependent decrease of important pro-inflammatory cytokines (TREM1, TNF-α, IL-1β) in cultured BMCs extracted from hydrogel treated mice was observed, possibly correlated to the anti-inflammatory effect of hyaluronic acid released in time as hydrogel degraded. This in vivo study established the suitability of the proposed hydrogel technology as promising matrix for tissue engineering and drug delivery. The possibility to apply the developed hydrogel technology in vivo will potentially bring advances in the biomedical and pharmaceutical fields.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
